Maze Therapeutics (NASDAQ:MAZE) CMO Harold Bernstein Sells 4,432 Shares

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 4,432 shares of the stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $40.43, for a total value of $179,185.76. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Harold Bernstein also recently made the following trade(s):

• On Monday, January 5th, Harold Bernstein sold 412 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.00, for a total value of $16,480.00.
• On Monday, December 29th, Harold Bernstein sold 45,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.56, for a total value of $1,825,200.00.

Maze Therapeutics Trading Down 0.7%

Shares of MAZE stock opened at $38.37 on Wednesday. The firm has a market capitalization of $1.85 billion and a P/E ratio of -1.84. Maze Therapeutics, Inc. has a 1 year low of $6.71 and a 1 year high of $43.29. The firm’s fifty day simple moving average is $37.28 and its 200 day simple moving average is $25.45.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.08.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on MAZE. HC Wainwright lifted their target price on shares of Maze Therapeutics from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, December 3rd. Guggenheim restated a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a research note on Friday, December 19th. Raymond James Financial initiated coverage on Maze Therapeutics in a research note on Thursday, November 13th. They issued an “outperform” rating and a $48.00 price objective on the stock. Lifesci Capital raised Maze Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Maze Therapeutics in a research report on Wednesday, October 8th. Three research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $43.38.

Institutional Trading of Maze Therapeutics

Several large investors have recently added to or reduced their stakes in MAZE. Ameritas Investment Partners Inc. raised its stake in shares of Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after acquiring an additional 738 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in Maze Therapeutics by 947.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after purchasing an additional 1,725 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new position in Maze Therapeutics in the 3rd quarter valued at $52,000. CWM LLC acquired a new position in Maze Therapeutics in the second quarter worth $28,000. Finally, Legal & General Group Plc boosted its stake in Maze Therapeutics by 387.0% in the second quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock worth $52,000 after purchasing an additional 3,371 shares in the last quarter.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.